Cargando…

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678

Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target gene, atpE, are rare in clinical isolates, mutations in the Rv0678 gene, a transcript...

Descripción completa

Detalles Bibliográficos
Autores principales: Snobre, J., Villellas, M. C., Coeck, N., Mulders, W., Tzfadia, O., de Jong, B. C., Andries, K., Rigouts, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300004/
https://www.ncbi.nlm.nih.gov/pubmed/37369740
http://dx.doi.org/10.1038/s41598-023-36955-y
_version_ 1785064491330830336
author Snobre, J.
Villellas, M. C.
Coeck, N.
Mulders, W.
Tzfadia, O.
de Jong, B. C.
Andries, K.
Rigouts, L.
author_facet Snobre, J.
Villellas, M. C.
Coeck, N.
Mulders, W.
Tzfadia, O.
de Jong, B. C.
Andries, K.
Rigouts, L.
author_sort Snobre, J.
collection PubMed
description Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target gene, atpE, are rare in clinical isolates, mutations in the Rv0678 gene, a transcriptional repressor regulating the efflux pump MmpS5-MmpL5, are increasingly observed, and have been linked to worse treatment outcomes. Nevertheless, underlying mechanisms of (cross)-resistance remain incompletely resolved. Our study aims to distinguish resistance associated variants from other polymorphisms, by assessing the in vitro onset of mutations under drug pressure, combined with their impact on minimum inhibitory concentrations (MICs) and on protein stability. For this purpose, isolates were exposed in vitro to sub-lethal concentrations of BDQ or clofazimine (CFZ). Selected colonies had BDQ- and CFZ-MICs determined on 7H10 and 7H11 agar. Sanger sequencing and additional Deeplex Myc-TB and whole genome sequencing (WGS) for a subset of isolates were used to search for mutations in Rv0678, atpE and pepQ. In silico characterization of relevant mutations was performed using computational tools. We found that colonies that grew on BDQ medium had mutations in Rv0678, atpE or pepQ, while CFZ-exposed isolates presented mutations in Rv0678 and pepQ, but none in atpE. Twenty-eight Rv0678 mutations had previously been described among in vitro selected mutants or in patients’ isolates, while 85 were new. Mutations were scattered across the Rv0678 gene without apparent hotspot. While most Rv0678 mutations led to an increased BDQ- and/or CFZ-MIC, only a part of them surpassed the critical concentration (69.1% for BDQ and 87.9% for CFZ). Among the mutations leading to elevated MICs for BDQ and CFZ, we report a synonymous Val1Val mutation in the Rv0678 start codon. Finally, in silico characterization of Rv0678 mutations suggests that especially the C46R mutant may render Rv0678 less stable.
format Online
Article
Text
id pubmed-10300004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103000042023-06-29 Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678 Snobre, J. Villellas, M. C. Coeck, N. Mulders, W. Tzfadia, O. de Jong, B. C. Andries, K. Rigouts, L. Sci Rep Article Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target gene, atpE, are rare in clinical isolates, mutations in the Rv0678 gene, a transcriptional repressor regulating the efflux pump MmpS5-MmpL5, are increasingly observed, and have been linked to worse treatment outcomes. Nevertheless, underlying mechanisms of (cross)-resistance remain incompletely resolved. Our study aims to distinguish resistance associated variants from other polymorphisms, by assessing the in vitro onset of mutations under drug pressure, combined with their impact on minimum inhibitory concentrations (MICs) and on protein stability. For this purpose, isolates were exposed in vitro to sub-lethal concentrations of BDQ or clofazimine (CFZ). Selected colonies had BDQ- and CFZ-MICs determined on 7H10 and 7H11 agar. Sanger sequencing and additional Deeplex Myc-TB and whole genome sequencing (WGS) for a subset of isolates were used to search for mutations in Rv0678, atpE and pepQ. In silico characterization of relevant mutations was performed using computational tools. We found that colonies that grew on BDQ medium had mutations in Rv0678, atpE or pepQ, while CFZ-exposed isolates presented mutations in Rv0678 and pepQ, but none in atpE. Twenty-eight Rv0678 mutations had previously been described among in vitro selected mutants or in patients’ isolates, while 85 were new. Mutations were scattered across the Rv0678 gene without apparent hotspot. While most Rv0678 mutations led to an increased BDQ- and/or CFZ-MIC, only a part of them surpassed the critical concentration (69.1% for BDQ and 87.9% for CFZ). Among the mutations leading to elevated MICs for BDQ and CFZ, we report a synonymous Val1Val mutation in the Rv0678 start codon. Finally, in silico characterization of Rv0678 mutations suggests that especially the C46R mutant may render Rv0678 less stable. Nature Publishing Group UK 2023-06-27 /pmc/articles/PMC10300004/ /pubmed/37369740 http://dx.doi.org/10.1038/s41598-023-36955-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Snobre, J.
Villellas, M. C.
Coeck, N.
Mulders, W.
Tzfadia, O.
de Jong, B. C.
Andries, K.
Rigouts, L.
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title_full Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title_fullStr Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title_full_unstemmed Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title_short Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
title_sort bedaquiline- and clofazimine- selected mycobacterium tuberculosis mutants: further insights on resistance driven largely by rv0678
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300004/
https://www.ncbi.nlm.nih.gov/pubmed/37369740
http://dx.doi.org/10.1038/s41598-023-36955-y
work_keys_str_mv AT snobrej bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT villellasmc bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT coeckn bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT muldersw bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT tzfadiao bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT dejongbc bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT andriesk bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678
AT rigoutsl bedaquilineandclofazimineselectedmycobacteriumtuberculosismutantsfurtherinsightsonresistancedrivenlargelybyrv0678